CT47A7: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

Target Name: CT47A7

NCBI ID: G653282

CT47A7

CT47A7: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

CT47A7 is a cancer antigen that is expressed in various tissues, including the brain, spleen, thymus, and lymph nodes. It is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region. CT47A7 is also known as cancer/testis antigen 47 (CT47) and has been identified as a potential drug target and biomarker for cancer and testis antigens.

Potential Drug Target

CT47A7 has been shown to play a critical role in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. It is highly expressed in cancer tissues and has been identified as a potential drug target. Several studies have shown that inhibiting the activity of CT47A7 can lead to the regression of established cancer tumors. Additionally, there are reports that targeting CT47A7 with small molecules has led to the inhibition of cancer cell proliferation and the regression of established tumors.

Biomarker

CT47A7 has also been identified as a potential biomarker for cancer. Its high expression in cancer tissues makes it a promising marker for the diagnosis and monitoring of cancer. Studies have shown that the level of CT47A7 is significantly increased in cancer tissues compared to normal tissues. Additionally, the level of CT47A7 has been shown to be decreased in cancer-free tissues after treatment with chemotherapy or radiation therapy. This suggests that CT47A7 may be a useful biomarker for monitoring the effectiveness of cancer treatments.

Expression and localization

CT47A7 is expressed in various tissues and has been shown to localize to specific organs and tissues. In the brain, CT47A7 is primarily expressed in the astrocytes and glial cells. In the spleen, CT47A7 is primarily expressed in the B cells and dendritic cells. In the thymus, CT47A7 is primarily expressed in the T cells. In the lymph nodes, CT47A7 is primarily expressed in the B cells and T cells.

Function and interactions

The function of CT47A7 is not well understood, but it is thought to play a role in the immune response. CT47A7 has been shown to interact with several immune molecules, including T-cell receptor 4 (TCR4), which is a critical molecule for T cell activation and proliferation. Additionally, CT47A7 has been shown to interact with the protein PD-L1, which is a negative regulator of T cell proliferation.

Conclusion

CT47A7 is a cancer antigen that is expressed in various tissues and has been identified as a potential drug target and biomarker for cancer and testis antigens. Its high expression in cancer tissues and its potential interactions with immune molecules make it a promising marker for cancer diagnosis and treatment. Further research is needed to fully understand the role of CT47A7 in cancer and testis antigens and its potential as a drug target and biomarker.

Protein Name: Cancer/testis Antigen Family 47 Member A7

The "CT47A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets